Galactose
- Generic Name
- Galactose
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12O6
- CAS Number
- 59-23-4
- Unique Ingredient Identifier
- X2RN3Q8DNE
- Background
Galactose has been used in trials studying the treatment and diagnosis of Hepatitis C, Hepatic Cancer, Wilsons Disease, Diabetic Macular Oedema, and Focal Segmental Glomerulosclerosis, among others. There are even proposals for its use in accelerating senescence in mice, rats, and Drosophila, for its association with ovarian cancer, or even for the potential...
- Indication
There are limited therapeutic uses for which galactose is formally indicated. Some predominant indications include (a) the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines , and (b) the role galactose plays as an essential element in the formation of lactulose - a synthetic disaccharide indicat...
- Associated Conditions
- -
- Associated Therapies
- -
sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 33
- Registration Number
- NCT02702765
- Locations
- π©π°
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 71
- Registration Number
- NCT02528461
- Locations
- π©π°
Aarhus University Hospital, Aarhus C, Denmark
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- University of Louisville
- Registration Number
- NCT01882218
- Locations
- πΊπΈ
University of Louisville Hospital, Louisville, Kentucky, United States
πΊπΈNorton Hospital, Louisville, Kentucky, United States
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Children's National Research Institute
- Target Recruit Count
- 7
- Registration Number
- NCT01113385
- Locations
- πΊπΈ
Children's National Medical Center, Washington DC, District of Columbia, United States
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2015-09-10
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 15
- Registration Number
- NCT00816478
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Northwell Health
- Registration Number
- NCT00816504
- Locations
- πΊπΈ
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 32
- Registration Number
- NCT00814255
- Locations
- πΊπΈ
University of Michigan, Ann Arbor, Michigan, United States
πΊπΈChildren's Mercy Hospital, Kansas City, Missouri, United States
πΊπΈCardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.